GTB-1550

N/A

Report date: 2023/05/17 20:00:39

Base Information

Drug NameGTB-1550
Drug Alias NameAnti-CD19-anti-CD22-diphtheria-toxin-fusion-proteinOXS-1550IND-100780DT-2219DT-2219ARL
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionCD22 modulatorsProtein biosynthesis inhibitorsAnti-CD19
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, B-CellLymphomaLeukemia, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMasonic Cancer Center, University Of Minnesota
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellLymphomaLeukemia, B-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A